HIMS Hims & Hers Health, Inc. — earnings, filings & institutional moves

Price chart

Daily historical data with per-account defaults

Latest close

$32.73

Period return

+2.21 (+7.24%)

Volume

7.3M

2026-07-21O $32.52 H $33.84 L $32.06 C $32.73MA5 $33.82MA20 $34.69MA60 $29.66MA120 $25.47

6M · 124 barsYahoo Finance · USD2026-01-22 → 2026-07-21

Recent event timeline

Filings, earnings, research, and institutional changes — newest first

View all →

2026. 08. 10.Highin 20 days
다음 실적 발표 예정
예정된 실적 발표입니다. 일정과 시장 기대치를 확인하세요.
2026. 05. 27.LowHOLD2 months ago
B of A Securities: Neutral
US analyst rating / recommendation change.
2026. 05. 23.LowHOLD2 months ago
Truist Securities: Hold
US analyst rating / recommendation change.
2026. 05. 20.LowHOLD2 months ago
B of A Securities: Neutral
US analyst rating / recommendation change.
2026. 05. 13.LowHOLD2 months ago
B of A Securities: Neutral
US analyst rating / recommendation change.
2026. 05. 13.LowHOLD2 months ago
Citigroup: Neutral
US analyst rating / recommendation change.
2026. 05. 13.LowBUY2 months ago
JP Morgan: Overweight
US analyst rating / recommendation change.
2026. 05. 12.LowHOLD2 months ago
BTIG: Neutral
US analyst rating / recommendation change.
2026. 05. 12.LowBUY2 months ago
Needham: Buy
US analyst rating / recommendation change.
2026. 04. 24.MediumBUY3 months ago
JP Morgan: Overweight
US analyst rating / recommendation change.

Recent earnings

Consensus vs. actual, and revenue trend

Earnings tab →

Research actions

Consensus PT $26.61 · 14 analysts

Research tab →

AI Brief (Premium)

Automated summary from public sources · not investment advice

Brief tab →

No AI brief generated yet. You can create one from the Brief tab.

Top institutions (13F)

Ranked by position value

Institutions tab →

Company info

Hims & Hers Health, Inc. operates as a consumer-first health and wellness platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, Canada, Germany, the Republic of Ireland, France, Spain, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides personalized health and wellness products; over-the-counter drug and device products, cosmetics, and supplement products primarily focusing on general wellness, skincare, sexual health and wellness, and hair care under the Hims & Hers brand name; and laboratory testing services to measure a set of biomarkers. Additionally, it offers medical consultation, post-consultation support services, and delivery of laboratory testing results services. Further, the company provides treatments and products for various chronic conditions related to hormone health, weight loss, dermatology, and mental health. The company offers its products through retail partnerships, in stores, and online. Hims & Hers Health, Inc. is based in San Francisco, California.

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
HQ: San Francisco, CA, United States

Quarter	Date	Time	EPS est.	EPS actual	Surprise	Rev. est.	Rev. actual	Status
—	2026. 08. 10.	After market close (AMC)	$0.13	—	—	$688.78M	—	Scheduled
FY2026 Q1	2025. 03. 31.	Time TBD	—	$0.2	—	—	$586.01M	Reported
FY2025 Q3	2024. 09. 30.	Time TBD	—	$0.43	—	—	$995.38M	Reported
FY2025 Q2	2024. 06. 30.	Time TBD	—	$0.11	—	—	$593.82M	Reported

Hims & Hers Health, Inc.힘스앤허스

Price chart

Recent event timeline

Recent earnings

Research actions

Top news

Key stats

Date	Firm	Analyst	Action	Rating change	Price target	Report
2026. 05. 27.	B of A Securities	—	Maintain	Neutral → Neutral	—	B of A Securities: Neutral
2026. 05. 23.	Truist Securities	—	Maintain	Hold → Hold	—	Truist Securities: Hold
2026. 05. 20.	B of A Securities	—	Maintain	Neutral → Neutral	—	B of A Securities: Neutral
2026. 05. 13.	B of A Securities	—	Maintain	Neutral → Neutral	—	B of A Securities: Neutral
2026. 05. 13.	Citigroup	—	Maintain	Neutral → Neutral	—	Citigroup: Neutral
2026. 05. 13.	JP Morgan	—	Maintain	Overweight → Overweight	—	JP Morgan: Overweight